Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,361 active trials259 approved drugs3,860 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,753 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05168202 | A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes | terminated | Phase 1 | 56 | Bristol-Myers SquibbINDUSTRY | 9 | Sep 25, 2025 | clinicaltrials |
| NCT05821777 | A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 25 | Centessa Pharmaceuticals (UK) LimitedINDUSTRY | 2 | Sep 25, 2025 |
| NCT06018129 | A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 9 | GenmabINDUSTRY | 2 | Sep 25, 2025 | clinicaltrials |
| NCT06264921 | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | terminated | Phase 1 | 23 | NiKang Therapeutics, Inc.INDUSTRY | 1 | Sep 25, 2025 | clinicaltrials |
| NCT04674748 | To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550 | terminated | Phase 1 | 3 | Incyte Biosciences Japan GKINDUSTRY | 1 | Sep 24, 2025 | clinicaltrials |
| NCT03769181 | A Study of Isatuximab-based Therapy in Participants With Lymphoma | terminated | Phase 1 / Phase 2 | 58 | SanofiINDUSTRY | 7 | Sep 23, 2025 | clinicaltrials |
| NCT05200364 | A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer | terminated | Phase 1 | 58 | Sutro Biopharma, Inc.INDUSTRY | 1 | Sep 22, 2025 | clinicaltrials |
| NCT05961839 | Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | terminated | Phase 1 | 66 | Schrödinger, Inc.INDUSTRY | 1 | Sep 22, 2025 | clinicaltrials |
| NCT06270082 | Study of IK-595 in RAS- or RAF-altered Advanced Tumors | terminated | Phase 1 | 75 | Ikena OncologyINDUSTRY | 1 | Sep 19, 2025 | clinicaltrials |
| NCT03446040 | An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread | terminated | Phase 1 / Phase 2 | 92 | Bristol-Myers SquibbINDUSTRY | 4 | Sep 18, 2025 | clinicaltrials |
| NCT06182579 | Phase I Study of RiMO-401 With Radiation in Advanced Tumors | terminated | Phase 1 | 5 | Coordination Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 17, 2025 | clinicaltrials |
| NCT06285097 | A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors | terminated | Phase 1 | 9 | PfizerINDUSTRY | 3 | Sep 17, 2025 | clinicaltrials |
| NCT04023331 | 67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma | terminated | Phase 1 / Phase 2 | 21 | Clarity Pharmaceuticals LtdINDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT04242147 | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid Tumors | terminated | Phase 1 | 45 | Kadmon, a Sanofi CompanyINDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT05904496 | A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 44 | BeiGeneINDUSTRY | 4 | Sep 16, 2025 | clinicaltrials |
| NCT06338657 | FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer | terminated | Phase 1 | 1 | University of Southern CaliforniaOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT03307759 | Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma(SABRseq) | terminated | Phase 1 | 13 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT04278144 | A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors | terminated | Phase 1 / Phase 2 | 175 | Bolt Biotherapeutics, Inc.INDUSTRY | 4 | Sep 15, 2025 | clinicaltrials |
| NCT05013554 | Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors | terminated | Phase 1 | 44 | SanofiINDUSTRY | 6 | Sep 15, 2025 | clinicaltrials |
| NCT05733351 | Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer | terminated | Phase 1 | 4 | Emory UniversityOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT05707676 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LB4330 in Patients With Advanced Solid Tumors（MEETCD8-001）(MEETCD8-001) | terminated | Phase 1 | 40 | L & L Bio Co., Ltd., Ningbo, ChinaINDUSTRY | 1 | Sep 11, 2025 | clinicaltrials |
| NCT06226766 | JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors | terminated | Phase 1 / Phase 2 | 11 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Sep 10, 2025 | clinicaltrials |
| NCT03838367 | Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC | terminated | Phase 1 / Phase 2 | 10 | CytoDyn, Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT04502082 | Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1) | terminated | Phase 1 | 8 | Eureka Therapeutics Inc.INDUSTRY | 1 | Sep 8, 2025 | clinicaltrials |
| NCT05662670 | A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 14 | Suzhou Junjing BioSciences Co., Ltd.INDUSTRY | 1 | Sep 8, 2025 | clinicaltrials |
| NCT05626322 | Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma | terminated | Phase 1 / Phase 2 | 6 | PfizerINDUSTRY | 3 | Sep 5, 2025 | clinicaltrials |
| NCT06016270 | A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 10 | STCube, Inc.INDUSTRY | 2 | Sep 5, 2025 | clinicaltrials |
| NCT01198067 | Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia | terminated | Phase 1 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT04989387 | Study of INCA 0186 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 57 | Incyte CorporationINDUSTRY | 6 | Sep 2, 2025 | clinicaltrials |
| NCT05490043 | A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas | terminated | Phase 1 | 33 | Antengene (Hangzhou) Biologics Co., Ltd.INDUSTRY | 1 | Aug 29, 2025 | clinicaltrials |
| NCT02423902 | A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer | terminated | Phase 1 / Phase 2 | 9 | Alaunos TherapeuticsINDUSTRY | 1 | Aug 28, 2025 | clinicaltrials |
| NCT05605522 | A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours | terminated | Phase 1 | 19 | 3B Pharmaceuticals GmbHINDUSTRY | 2 | Aug 24, 2025 | clinicaltrials |
| NCT06679582 | Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML | terminated | Phase 1 / Phase 2 | 24 | Sutro Biopharma, Inc.INDUSTRY | 9 | Aug 24, 2025 | clinicaltrials |
| NCT06074705 | A Study of DS-1471a In Subjects With Advanced Solid Tumors | terminated | Phase 1 | 17 | Daiichi Sankyo Co., Ltd.INDUSTRY | 2 | Aug 22, 2025 | clinicaltrials |
| NCT06508489 | A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies | terminated | Phase 1 / Phase 2 | 7 | SanofiINDUSTRY | 2 | Aug 22, 2025 | clinicaltrials |
| NCT02784795 | A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 94 | Eli Lilly and CompanyINDUSTRY | 4 | Aug 21, 2025 | clinicaltrials |
| NCT05109442 | Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers | terminated | Phase 1 / Phase 2 | 112 | Affimed GmbHINDUSTRY | 5 | Aug 20, 2025 | clinicaltrials |
| NCT05388877 | E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma | terminated | Phase 1 | 13 | Mayo ClinicOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT02807597 | Real-time Intraoperative Breast Cancer Visualization for Margin Assessment | terminated | Phase 1 / Phase 2 | 9 | Samuel AchilefuOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT03015792 | Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant | terminated | Phase 1 | 18 | Mayo ClinicOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT05708924 | MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | terminated | Phase 1 | 1 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT07121829 | Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors | terminated | Phase 1 | 44 | Day One Biopharmaceuticals, Inc.INDUSTRY | 2 | Aug 14, 2025 | clinicaltrials |
| NCT03330197 | A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG | terminated | Phase 1 / Phase 2 | 6 | Alaunos TherapeuticsINDUSTRY | 1 | Aug 12, 2025 | clinicaltrials |
| NCT04611126 | T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer | terminated | Phase 1 / Phase 2 | 6 | Inge Marie SvaneOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT05109650 | Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumour Patients | terminated | Phase 1 | 13 | Bio-Thera SolutionsINDUSTRY | 1 | Aug 12, 2025 | clinicaltrials |
| NCT05623488 | CAR T Cells in Mesothelin-Expressing Breast Cancer | terminated | Phase 1 | 2 | University of PennsylvaniaOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT05975645 | A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC). | terminated | Phase 1 | 29 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 12, 2025 | clinicaltrials |
| NCT02900651 | Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies | terminated | Phase 1 | 139 | Novartis PharmaceuticalsINDUSTRY | 10 | Aug 11, 2025 | clinicaltrials |
| NCT05032183 | Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | terminated | Phase 1 / Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Sep 25, 2025source: clinicaltrials